Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at Evercore ISI

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective increased by equities research analysts at Evercore ISI from $25.00 to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price target would suggest a potential upside of 70.36% from the stock’s current price.

Several other research analysts also recently weighed in on KNSA. TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a report on Thursday, February 29th. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA opened at $17.61 on Wednesday. The stock has a fifty day moving average of $19.32 and a two-hundred day moving average of $18.00. The company has a market capitalization of $1.24 billion, a PE ratio of 160.11 and a beta of 0.27. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The business had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The company’s revenue was up 65.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.18) earnings per share. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $377,262.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Michael R. Megna sold 5,126 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $383,242.52. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock valued at $709,929 in the last ninety days. Company insiders own 54.23% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth $65,000. China Universal Asset Management Co. Ltd. boosted its position in Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after purchasing an additional 3,186 shares during the period. Victory Capital Management Inc. purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth $176,000. Dynamic Technology Lab Private Ltd purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter worth $213,000. Finally, QRG Capital Management Inc. purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth $249,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.